Self-reported electronic symptom monitoring in older patients with multimorbidity treated for cancer: Development of a core dataset based on expert consensus, literature review, and quality of life questionnaires.

Autor: Nelleke Seghers PAL; Department of Geriatric Medicine, Diakonessenhuis, 3582, KE, Utrecht, the Netherlands. Electronic address: nseghers@diakhuis.nl., Hamaker ME; Department of Geriatric Medicine, Diakonessenhuis, 3582, KE, Utrecht, the Netherlands. Electronic address: mhamaker@diakhuis.nl., O'Hanlon S; Department of Geriatric Medicine, St Vincent's University Hospital, D04 T6F4 Dublin, Ireland; Department of Geriatric Medicine, University College Dublin, D04 V1W8 Dublin, Ireland. Electronic address: Shaneohanlon@svhg.ie., Portielje JEA; Department of Medical Oncology, Leiden University Medical Center-LUMC, 2333, ZA, Leiden, the Netherlands. Electronic address: j.e.a.portielje@lumc.nl., Wildiers H; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: hans.wildiers@uzleuven.be., Soubeyran P; Department of Medical Oncology, Institut Bergonié, Inserm U1312, SIRIC BRIO, Université de Bordeaux, 33076 Bordeaux, France. Electronic address: p.soubeyran@bordeaux.unicancer.fr., Coolbrandt A; Department of Oncology Nursing, University Hospitals Leuven, Leuven, Belgium; Department of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven, Leuven, Belgium. Electronic address: annemarie.coolbrandt@uzleuven.be., Rostoft S; Department of Geriatric Medicine, Oslo University Hospital, 0424 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway. Electronic address: siri.rostoft@medisin.uio.no.
Jazyk: angličtina
Zdroj: Journal of geriatric oncology [J Geriatr Oncol] 2024 Jan; Vol. 15 (1), pp. 101643. Date of Electronic Publication: 2023 Nov 16.
DOI: 10.1016/j.jgo.2023.101643
Abstrakt: Introduction: In cancer care, symptom monitoring during treatment results in improved clinical outcomes such as improved quality of life, longer survival, and fewer hospital admissions. However, as the majority of patients with cancer are older and have multimorbidity, they may benefit from monitoring of additional symptoms. The aim of this study was to identify a core set of symptoms to monitor in older patients with multimorbidity treated for cancer, including symptoms caused by treatment side effects, destabilization of comorbidities, and functional decline.
Materials and Methods: During a scoping literature search, 17 quality of life questionnaires were used to select 53 possible symptoms to monitor. An expert panel of cancer and geriatrics specialists was asked to participate in multiple online surveys to indicate whether these symptoms were not relevant to monitor, only relevant to monitor in a specific patient group, or relevant to monitor in all patients. In a subsequent round the list was reduced and the panel indicated how frequently these symptoms should be monitored during cancer treatment and after cancer treatment completion. Finally, a digital consensus meeting was organised to decide when symptoms had to trigger a recommendation to the patient to get in touch with their medical team.
Results: In total, 30 healthcare professionals participated in the online surveys. After two rounds, a dataset of 19 symptoms related to cancer, cancer treatment, functional decline, and destabilization of comorbidities was agreed upon for monitoring. Five symptoms were selected for daily monitoring during treatment, seven for weekly, and seven for monthly. After treatment completion, the panel agreed upon less frequent reporting. Additionally, nine symptoms to be monitored only in patients with specific cancer types or treatment types were chosen, such as "cough up blood" in lung cancer.
Discussion: This study is the first to identify a core set of symptoms to monitor in older patients with multimorbidity treated for cancer. Future research is needed to investigate whether the monitoring of these symptoms is feasible and improves clinical outcomes in older patients with multimorbidity treated for cancer.
Competing Interests: Declaration of Competing Interest Pierre Soubeyran: Board member with TEVA, Sandoz, BMS and EISAI. All other authors: No competing interests to declare.
(Copyright © 2023. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: